CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Biomed Lublin Wytwornia Surowic I Szczepionek SA Company Snapshot
Biomed Lublin Wytwornia Surowic I Szczepionek SA operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Biomed Lublin Wytwornia Surowic I Szczepionek SA with three other pharmaceutical manufacturers in Europe: Medincell SA of France (2018 sales of 6.44 million Euro [US$7.09 million] ), Curasan AG of Germany (5.84 million Euro [US$6.43 million] ), and Transgene which is based in France (7.08 million Euro [US$7.80 million] of which 81% was Research & Development Tax Credit).

Sales Analysis. Biomed Lublin Wytwornia Surowic I Szczepionek SA reported sales of 32.29 million Polish New Zlotys (US$8.19 million) for the year ending December of 2018. This represents an increase of 2.8% versus 2017, when the company's sales were 31.40 million Polish New Zlotys. Despite this increase, sales are still below the level achieved in 2016, when Biomed Lublin Wytwornia Surowic I Szczepionek SA reported sales of 36.34 million Polish New Zlotys. The sales level in 2018 was fairly close to the level five years ago: in 2013, Biomed Lublin Wytwornia Surowic I Szczepionek SA had sales of 32.98 million Polish New Zlotys.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Biomed Lublin Wytwornia Surowic I Szczepionek SA
  Stock Performance Chart for Biomed Lublin Wytwornia Surowic I Szczepionek SA
 
  Stock Data: Recent Stock Performance:
  Current Price (9/6/2019): .95
(Figures in Polish New Zlotys)
1 Week -4.8%   13 Weeks 0.2%  
4 Weeks 19.3%   52 Weeks -18.6%  
 
Biomed Lublin Wytwornia Surowic I Szczepionek SA Key Data:
  Ticker: BML Country: Poland
  Exchanges: WAR Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2018 Sales 32,293,000
(Year Ending Jan 2019).
Employees: 221
  Currency: Polish New Zlotys Market Cap: 59,271,910
  Fiscal Yr Ends: December Shares Outstanding: 62,260,410
  Share Type: Akcje Closely Held Shares: 28,938,112
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.